Catalyst Wire Dossier Catalyst Wire Dossier

tislelizumab (Tivdak)

tislelizumab · BeiGene
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for tislelizumab (Tivdak), covering 2024-05-17 to 2024-05-17. Get the full timeline:

Most recent: Clinical Trial Update: Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma [Phase 2]

See pricing